News

Access and download our newsletters from the Newsletter Archive

 
 

As well as keeping you up to date with the latest developments within the life sciences sector, Bionow members can also post updates to the Bionow News page to promote themselves to over 300 Bionow member organisations and the UK Life Sciences sector.

Whether currently a member or not, keep up to date with all the latest news and events by registering to receive the Bionow newsletter.

Francesco Maria Lavino appointed Chief Executive Officer of F2G Ltd

Apr 12th 2021
F2G Limited, a clinical-stage biopharmaceutical company focused on life threatening fungal diseases, announces that Francesco Maria Lavino has been appointed Chief Executive Officer (CEO) an...
Read More

F2G Closes US$60.8 Million Financing to fund late stage development of novel mec...

Aug 12th 2020
Financing round led by Cowen Healthcare Investments with strong support from existing investors Novo Holdings, Morningside Ventures, Brace Pharma Capital and Advent Life Sciences
Read More

F2G’s olorofim receives both FDA Orphan Drug Designation for Coccidioidomycosi...

Jun 10th 2020
F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that following the granting of Breakthrough Therapy desig...
Read More

F2G Receives US FDA Orphan Drug Designation for Olorofim

Mar 11th 2020
F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that the U.S. Food and Drug Administration (FDA) has gran...
Read More

F2G Receives US FDA Orphan Drug Designation for Olorofim

Mar 9th 2020
F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that the U.S. Food and Drug Administration (FDA) has gran...
Read More

F2G Receives US FDA Breakthrough Therapy Designation for Olorofim

Nov 11th 2019
F2G Ltd, a UK- and Austria-based biotech company developing novel therapies for life-threatening systemic fungal infections, announced today that the FDA has granted Breakthrough Therapy des...
Read More

EU supports F2G Biotech in Austria with EUR 24 million for antifungal research a...

Nov 22nd 2018
EIB financing strengthens F2G's research and innovation. Financing is provided under the InnovFin Infectious Diseases Finance Facility (IDFF) funded by Horizon 2020, the EU's research and in...
Read More

Search Site

  Latest Jobs

Sign up to our Newsletter

Our Valued Sponsors & Partners